Cleaning validation is an essential component of pharmaceutical manufacturing, as inadequate cleaning may result in the carryover of active pharmaceutical ingredients, excipients, cleaning agents, microorganisms, and other contaminants into subsequent products. Manufacturing facilities that are shared can impact product quality, patient safety, and regulatory compliance.

Traditionally, cleaning validation was often performed to validate individual products and cleaning processes with predefined acceptance criteria. In todays pharmaceutical manufacturing environment, a more scientific, risk-based approach is increasingly needed to consider factors such as product potency, toxicity, solubility, equipment design, cleanability, sampling locations, hold times, analytical sensitivity, and the risk of cross-contamination.

The principle is simple: the higher the risk, the higher the level of control and validation effort should be. This approach is consistent with ICH Q9 Quality Risk Management, which states that the amount of effort, formality, and documentation should be commensurate with the level of risk.

What Is Risk-Based Cleaning Validation?

Risk-based cleaning validation is a systematic approach to demonstrating that a cleaning process is capable of consistently removing product residues and other contaminants to predetermined acceptable levels, with greatest validation effort focused on higher risk situations.

Factors commonly looked at include:

• API strength and toxicity
• Health-related exposure limits
• Solubility and formulation of product
• Equipment construction and cleanability
• Areas that are difficult to clean
• Dirty and Clean Hold Times
• Temperature, time, and detergent concentration for cleaning
• Microbiological hazards
• Analytical method sensitivity
• Exposure risk to patient
  
  

The FDA expects cleaning validation to be supported by scientific data that a cleaning process consistently produces equipment that meets predetermined specifications. This process includes written procedures, protocols, acceptance criteria, sampling procedures, analytical methods, and validation reports.

Why Risk-Based Cleaning Validation Matters

Pharmaceutical facilities frequently use the same equipment to produce more than one product, creating the potential for carryover from one product to another. For example, consider a vessel used first to make Product A and then Product B. Product A has a very strong API. Even a small amount of residue could be important if Product B is given at a much lower dose.

Alternatively, a larger amount of a low-potency, highly soluble material may be less of a toxicological risk, but may still impact the quality of the final product. Therefore, the residue that is the easiest to detect is not necessarily the residue that poses the greatest risk to the patient.

A risk-based program asks two basic questions:

1. How hard is it to remove the residue?
2. What would be the consequences of leaving behind residues?
   
   

These questions help manufacturers determine where more validation effort is needed.

The Role of HBELs in Cleaning Validation

Health-based exposure limits, or HBELs, have become an important part of modern contamination-control strategies. An HBEL establishes a scientifically justified level of exposure to an active substance that is unlikely to cause appreciable harm under defined conditions. The EMA framework uses HBELs when assessing cross-contamination risks in shared facilities.

Consider two products manufactured using the same equipment. Product A has high potency, low solubility, a low HBEL, and residue that strongly adheres to stainless steel. Product B has lower potency, high solubility, a higher HBEL, and is easily removed.

A risk-based approach would identify Product A as the more challenging cleaning case and could require more stringent residue limits, additional sampling, greater analytical sensitivity, or more extensive cleaning studies. The purpose is not simply to increase testing but to focus resources where they provide the greatest reduction in risk.

Selecting the Worst-Case Product

Risk-based cleaning validation is a key component of worst-case selection.

The worst-case product is not always the product with the highest strength or lowest solubility. There are many factors to consider, such as:

• Potency and Toxicity
• HBEL or PDE 2
• Solubility
• Washability
• Adhesion properties
• Size of batch
• Surface area of equipment
• Characteristics of the formula
• Stability of residue
• Analytical detectability
  
  

Recent FDA enforcement activity has demonstrated the importance of scientifically justified worst-case selection. In a 2026 warning letter, the FDA cited deficiencies where a cleaning validation study did not include an appropriate worst-case product and emphasized factors including toxicity, potency, solubility, difficult-to-clean products, sampling locations, and maximum hold times.

Worst-case assessments should also be reassessed when new products, active pharmaceutical ingredients, equipment, formulations, cleaning agents, or toxicological information are introduced.

A Practical Worst-Case Scenario

Consider a tablet plant with standard granulator, blender, and compression equipment. Initially, Product X is chosen as the worst case due to its low solubility. Then the company rolls out Product Y with a very potent API but a significantly lower HBEL.

Product Y is more soluble, but its toxicological profile means that a much smaller amount of carryover could be significant. Thus, a risk-based reassessment may identify Product Y as the new worst-case product. If the company does not reconsider the original validation strategy and continues with it, the documented validation program may not be in agreement with the actual contamination risk.

Equipment Design and Cleanability

Cleaning validation starts with equipment design. Poor equipment can create residue traps that cleaning solutions cannot reach. Examples are dead legs, badly designed valves, gaskets, seals, narrow piping, transfer lines, spray shadows, and hard-to-access surfaces. Both the FDA and PIC/S put emphasis on equipment design and hard-to-clean areas as important aspects of cleaning validation.

Example of a Cleanability Risk

Take a stainless-steel mixing vessel, for example, with a spray-ball CIP system. The main vessel might look simple to clean, but a bad valve design creates a dead leg where cleaning solution doesn't flow much. Product residue builds up in this area during manufacturing. The valve is contaminated, whereas the main vessel may look fine.

A validation program based on risk would identify the valve as a critical sampling site, and perhaps require further development of cleaning cycles or equipment modification. This shows the necessity of choosing sampling sites based on risk and not convenience.

Swab Sampling and Rinse Sampling

Sampling provides evidence of effective cleaning. Swab sampling provides direct information on specific surfaces, while rinse sampling can provide broader coverage of hard-to-access areas. The right approach depends on the equipment and the risk.

A risk-based sampling plan may focus on:

• Sealing
• Valve seats
• Transfer centers
• Blades for mixing
• Corners for equipment
• Areas of spray-shade
• Piping which is difficult to get to
• Product discharge locations
  
  

Sampling a few high-risk locations might be more informative than sampling many easily accessible surfaces.

Cleaning Parameters and Process Understanding

The validated cleaning process should specify the parameters impacting the effectiveness of the cleaning.

Depending on the system, these could include:

• Cleaning temperature
• Cleaning time
• Concentration of detergent
• Rate of flow
• Stress
• Mechanical operation
• Volume of rinse
• Water quality
  
  

In CIP systems, flow velocity and temperature can directly affect the cleaning performance. Operator technique is a significant variable for manual cleaning.